×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Novartis: ARV-766 is an androgen receptor degrader efficacious in treating metastatic prostate cancer
2 Minute Medicine
In patients with metastatic prostate cancer, ARV-766 treatment led to a greater than 50% reduction in Prostate-Specific antigen (PSA) in 42%...
10 hours ago
Biopharma Layoff Tracker 2024: Bolt, Tenaya, BioMarin and More Cut Staff
BioSpace
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
5 hours ago
Novartis to showcase next-gen manufacturing solutions at BIO 2024
biopharma-reporter.com
Before the industry is set to arrive in San Diego for Bio International 2024, we spoke with Dr. Harald Oberegger, global head business...
21 hours ago
Research and development
Novartis
Research and development. We are an innovative medicines company with research and development at our core. Our R&D engine powers an industry-leading pipeline...
3 months ago
Novartis extends radiopharma plans with $1B acquisition of Mariana Oncology
STAT
The acquisition presents a new avenue for Novartis, which already sells the leading radiopharmaceutical drug, Pluvicto.
2 weeks ago
Novartis to buy radiology drug specialist Mariana for $1 billion
Reuters
Novartis agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront, boosting its portfolio of precision...
2 weeks ago
Novartis slammed again for discrediting pharma industry
Fierce Pharma
Novartis' Entresto team has earned the ire of the PMCPA. For the third time in 12 months, the U.K. drug promotion watchdog has found the...
6 days ago
Novartis to pay up to $1.75 billion for U.S. cancer-focused biotech
Morningstar
By Steve Goldstein. Pharmaceutical giant Novartis AG on Thursday said it will pay up to $1.75 billion for a U.S. biotech focused on cancer.
2 weeks ago
Drugmaker Novartis climbs after guidance rise on sales of blockbuster drugs
CNBC
Shares of Swiss drugmaker Novartis climbed as much as 4.8% in early deals Tuesday after it raised its full-year guidance following...
3 weeks ago
Novartis in Society Integrated Report
Novartis
In 2023, Novartis entered a new era. We spun off our generics business as part of a multi-year transformation to fully focus on innovative medicines.
3 months ago